

Stability Indicating Lc–Ms/Ms Method For Lamivudine And Nevirapine

B. Lavanya^{*1}, P. Shanmugasundaram²

^{1*}Department of Pharmaceutical Analysis, School of pharmaceutical sciences, Vels Institute of Science, Technology & Advanced Studies (VISTAS) Chennai 600117

Abstract

The aim of the stability studies is to perform to meet the quality, safety and efficacy. This type of study is used to know the changes in physical, chemical or microbiological properties of the drug with respect to time. Based on our study, noticed that Lamivudine and Nevirapine were stable to thermal stress. Percentage stability of all the stock solutions met the acceptance criteria. Working Solution percentage Stability values for Lamivudine and Nevirapine at LQC & HQC levels were 104.35 & 99.73% and 100.82 & 99.49%, respectively. Working Solution percentage Stability values for Lamivudine 13C 15N2 and Nevirapine D5 at LQC & HQC levels were 99.66 & 99.85% and 101.41 & 101.93, respectively. The stability studies were determined by calculating the Low Quality Control and High Quality Control samples percentage nominal beside freshly pointed, prepared calibration curve standards and compared with freshly spiked and prepared comparison samples at Low Quality Control and High Quality Control level..

Keywords: Autosampler stability, Bench top stability, Elution, Free Thaw Stability, Wetextract stability

Introduction

Antiretroviral drugs are used to treat infections by retro viruses, primarily the human immunodeficiency virus (HIV). The aim of antiretroviral treatment is to maintain Human Immuno Virus at a low level in the body. Since single drug therapy rapidly becomes ineffective due to the development of HIV resistant strains, the new paradigm is to combine two to three anti retro viral drugs. The synergistic action of different classes of antiretroviral drugs prolongs the survival of HIV patients such that combination therapy is now considered first-line treatment. Current treatment guidelines state that a combination antiretroviral regimen should contain at least one nucleoside analog reverse transcriptase inhibitor (NRTI) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) in a fixed dose combination. Lamivudine(20-deoxy-30-thiacy-tidine) is NRTI whereas Nevirapine (11-cyclopropyl-5,11-dihydro-4- methyl-6H- dipyrido[3,2-b:20, 30-e]1,4 diazepin-6-one) is a highly potent noncompetitive NNRTI. The validated method was applied to a clinical pharmacokinetics study involving formulations of Lamivudine and Nevirapine.

MATERIALS & METHODS

Reagents and chemicals

HPLC grade acetonitrile and potassium dihydrogen ortho phosphate buffer analytical grade were procured from Clearsynth Lab Limited, Mumbai, India. Analytes Lamivudine (99.92%), Nevirapine (99.95%) and co analyte Zidovudine (99.90%) were obtained from Clearsynth Lab Limited, Mumbai, India. pure standards of Lamivudine 13C 15N2 (99.43%) and Nevirapine D5 (99.53%)were obtained from Clearsynth Lab Limited, Mumbai, India. Blank K3EDTA human plasma lots were used for screening were obtained from Micro therapeutics Lab.

Instrumentation and Chromatographic Conditions

Chromatographic separation was carried out on a Waters HPLC with a Hypurity C18 (100 mm × 4.6 mm, 5.0 µm) column and a mobile phase consisting of Acetonitrile: buffer (75:25v/v) delivered at a flow rate of 1 mL/min. The injection volume was 5 ml. Quantitation was achieved in a run time of 2.5min by MS/MSdetection in the positive ion mode using an Quattro Micro Mass, Waters equipped with a Turbo ion spray TM interface at 600 1C and ion spray voltages et at 5500V. Source parameters viz. nebulizer gas(GS1), auxiliarygas(GS2), curtain gas(CUR) and collision gas(CAD) were set at 35, 35, 20 and 6psi,respectively.vCompoundvparameters viz. declustering potential(DP), collisionenergy(CE), entrance potential (EP) and collision cellex it potential(CXP) were respectively 36,16,10 and 6V for lamivudine,70,44,10 and 6V for nevirapine. Detection was supported out by selective reaction monitoring (SRM) of the transitions (precursor ion to product ion) at m/z 230.10-112.05 for lamivudine, m/z 267.16-225.95 for nevirapine and m/z 233.27-115.20 for Lamivudine 13C 15N2, m/z 272.19-226.99 for Nevirapine D5. Quadrupoles Q1and Q3were set on unitre solution. Data Acquisition – Mass Lynx version 4.1 SCN627 supplied by Waters India Ltd.

Sample Preparation

Add 50 μ L of internal standard solution Lamivudine 13C 15N2- 5 μ g/ml and Nevirapine D5- 10 μ g/ml into all individually labeled vacant Radioimmunoassay(RIA) vials except blank. Pipette 300 μ L of plasma samples into respectively labeled RIA vials containing standard solution

Add 200 μL of Buffer into all the samples.

Load the samples into catridges.

STABILITY

Freeze-Thaw Stability

Lamivudine and Nevirapine six replicates were determined in K3EDTA human plasma at Low Quality Control and High Quality Control concentration after four cycles of freeze thaw (at both -70°C \pm 15°C and -30°C \pm 10°C storage temperatures). The stability studies were resolute by calculate the Low Quality Control and High Quality Control samples percentage nominal against freshly spiked, prepared calibration curve standards and compared with freshly pointed and prepared relationship samples at Low Quality Control and High Quality Control level.

Lamivudine:

The average percentage nominal of FT4 (Fourth Freeze Thaw cycle) stability samples calculated against freshly spiked, prepared CC at LQC and HQC concentrations for -70° C ± 15°C and -30° C ± 10°C were 96.01 & 93.75% and 98.31 & 94.27%, respectively. The average percentage nominal of

stability samples when related with freshly spiked, prepared comparison samples at LQC and HQC levels for - $70^{\circ}C \pm 15^{\circ}C$ and - $30^{\circ}C \pm 10^{\circ}C$ were 90.53 & 98.93% and 92.71 & 99.48%, respectively four freeze thaw stability cycles (refer Table 1) demonstrating acceptable.

Nevirapine:

The average percentage nominal of FT4 (Fourth Freeze Thaw cycle) stability samples calculated against freshly spiked, prepared CC at LQC and HQC concentrations for -70° C ± 15°C and -30° C ± 10°C were 95.84 & 95.81% and 95.00 & 94.65%, respectively. The mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels for -70° C ± 15°C and -30° C ± 10°C were 94.47 & 99.07% and 93.64 & 97.86%, respectively demonstrating acceptable four freeze thaw stability cycles (refer Table 2)

Bench-Top Stability

Bench top stability of Lamivudine and Nevirapine was estimated at room temperature in K3EDTA human plasma. LQC and HQC Six duplicate samples were processed for about 15.15 hours after keeping the samples on worktop. Bench top stability will be calculated by evaluating the stability of samples against freshly spiked. Should be placed on the bench for 4 to 24 hours and kept on bench during extraction process.

Lamivudine:

Stability studies were calculated by freshly prepared calibaration curve at Low Quality Control and High Quality Control levels were found to be 99.07 and 95.16%. Mean percentage nominal of stability samples at LQC and HQC levels were 93.42 & 100.41%, respectively, representing acceptable bench-top stability at room temperature for at least 15.15 hours (refer Table 3).

Nevirapine:

The mean percentage nominal of bench top stability samples calculated against freshly prepared CC at LQC and HQC levels were 97.59 & 94.37%, respectively and the mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were 96.19 & 97.57%, respectively, representing suitable bench-top stability at room temperature for at least 15.15 hours (refer Table 4).

Auto Sampler Stability for Lamivudine and Nevirapine

Autosampler stability is for to establish to prove the stability of samples in auto sampler at 10°C for 45.10 hours. It is calculated with processed samples by calculating samples percentage nominal against freshly spiked.

Lamivudine:

The average percentage nominal of auto sampler stability samples was calculated against freshly spiked and prepared CC at both Low and High quality control levels after 45.10 hours at 10°C was 102.89 & 114.42% and the mean percentage nominal of stability samples

when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were 104.75 & 105.54% demonstrating acceptable auto sampler stability for at least 45.10 hours at 10°C (refer Table).

Nevirapine:

The average percentage nominal of auto sampler stability samples was calculated against freshly spiked and prepared CC at LQC and HQC levels after 45.10 hours at 10°C was 99.71 & 98.85% and the mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were 97.74 & 100.22% demonstrating acceptable auto sampler stability for at least 45.10 hours at 10°C.

Auto Sampler Stability for Internal Standard

Auto sampler stability for six replicates of both Low Quality Control and High Quality Control samples were processed in auto sampler at 10°C for 45.10 hours. Autosampler stability was done by comparing the internal standard area of freshly sharp and prepared comparison QC samples at LQC and HQC levels against the internal standard area of stability samples.

The percentage of auto sampler stability for Lamivudine 13C 15N2 and Nevirapine D5 were calculated by compared with comparison samples at LQC and HQC levels was 90.84 and 99.32% demonstrating acceptable auto sampler stability for at least 45.10 hours at 10°C.

Wet Extract Stability

Wet Extract Stability in Refrigerator

Wet extract stability for six replicates were processed and transferred into injector vials and stored at 2-8°C for 50.47 hours then transferred into autosampler and finally determined.

Lamivudine:

The average percentage nominal of wet extract stability in refrigerator samples calculated against freshly prepared CC at LQC and HQC after 50.47 hours were 98.55 & 94.94%, respectively. The mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were found to be 92.93 & 100.18%, respectively representing suitable wet extract stability

Nevirapine:

The values of freshly prepared CC at LQC and HQC after 50.47 hours were 97.14 & 95.00%, respectively. The mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were found to be 95.75 & 98.22%, respectively demonstrating acceptable wet extract stability in refrigerator at 50.47 hours.

Wet Extract Stability at Room temperature

Wet extract stability at room temperature for six replicates were processed and transferred into injector vials and stored at room temperature for 06.33 hours then transferred into autosampler and finally comparison at LQC and HQC level.

Lamivudine:

Wet extract stability in room temperature, samples calculated against freshly prepared calibration curve at Low Quality Control and High Quality Control after 06.33 hours were 95.30 & 93.80%. The mean percentage nominal of stability samples when compared with freshly spiked, prepared

comparison samples at LQC and HQC levels were found to be 89.87 & 98.98%, respectively demonstrating acceptable wet extract stability for atleast 06.33 hours at room temperature.

Nevirapine:

Values of freshly prepared Calibration curve at Low Quality Control and High Quality Control after 06.33 hours were 97.49 & 94.95%, respectively. The mean percentage nominal of stability samples when compared with freshly spiked, prepared comparison samples at LQC and HQC levels were found to be 96.10 & 98.17%, respectively demonstrating acceptable wet extract stability for atleast 06.33 hours at room temperature.

Effect of Haemolysis on Lamivudine and Nevirapine

Effect of haemolysis on Lamivudine and Nevirapine in K3EDTA haemolyzed matrix was estimated at 20-250c. LQC and HQC samples were spiked in haemolyzed matrix and six replicates of each LQC and HQC levels were processed as per method SOP along with freshly spiked and prepared calibration curve standards in normal plasma. Prepared calibration curve standards and haemolyzed LQC and HQC samples were analysed.

The mean percentage nominal and %CV of haemolytic effect of Lamivudine at LQC & HQC levels were 107.42 & 103.70% and 4.69 & 1.62% and for Nevirapine, 102.13 & 99.06% and 3.82 & 0.87%, respectively.

Stock Solution Stability Experiments

Working Solution Stability for Lamivudine and Nevirapine

The stock solution 1001.9978 μ g/mL and 1011.2941 μ g/mL of Lamivudine and Nevirapine, respectively were divided in two portions. Part one is diluted with two stages of low and high concentration should be placed on the top for 40.43 hours at room temperature and other part is in cold place. The stability of the Lamivudine and Nevirapine stock solution should be keep on the top at room temperature for 40.43 hours (low and high) were compared against the freshly prepared stock solutions at LQC and HQC level from the other portion stored in the fridge.The percentage stability of Lamivudine and Nevirapine at LQC & HQC levels were 104.35 & 99.73% and 100.82 & 99.49%, respectively.

Working Solution Stability for Internal Standard

Concentrations of stock solutions 1011.9985 μ g/mL and 1001.6699 μ g/mL of Lamivudine 13C 15N2 and Nevirapine D5, respectively were divided in two portions. One solution was diluted to internal standard solution keep it on top at room temperature for 40.43 hours and other solution is placed in refrigerator. The percentage stability of Lamivudine 13C 15N2 and Nevirapine D5 at LQC & HQC levels were 99.66 & 99.85% and 101.41 & 101.93, respectively.


Short-Term Stock Solution Stability for Lamivudine and Nevirapine

The stock solution 1001.9978 μ g/mL and 1011.2941 μ g/mL of Lamivudine and Nevirapine, respectively were divided in two parts. One portion was placed on bench at 20-250c for 43.62 hours and other portion in cold place until analysis. Two of the stock solutions were diluted after intended storage at two levels of low and high (LQC and HQC) concentration. The stability of both the stock

solutions keep at a temperature of 20-250c for a duration of 43.62 hours should compared against the freshly prepared stock solutions at low and high quality control level from other portion in refrigerator. The percentage stability of Lamivudine and Nevirapine at LQC & HQC were 103.83 & 103.93% and 99.91 & 101.76%, respectively (refer table 5, 7 and 9, 11).

Short-Term Stock Solution Stability for Internal Standard

The stock solution 1011.9985 μ g/mL and 1001.6699 μ g/mL of Lamivudine 13C 15N2 and Nevirapine D5, respectively were divided in two portions. One portion was placed on bench at room temperature for 43.62 hours and other portion in refrigerator until analysis. Both the stock solutions were diluted after intended storage to internal standard concentration and placed on the bench at room temperature for 43.62 hours was compared against the freshly prepared internal standard of intended concentration stored in the refrigerator from other portion. The percentage stability of Lamivudine 13C 15N2 and Nevirapine D5 a LQC & HQC levels were 97.40 & 97.47% and 97.49 & 98.12% (refer table 6, 8 and 10, 12).






Figure 3: Representative Chromatogram of INTQC Sample for Lamivudine




Figure 4: Representative Chromatogram of MQC Sample for Lamivudine




Figure 5: Representative Chromatogram of HQC Sample for Lamivudine




Figure 6: Representative Chromatogram of INTQC Sample for Nevirapine

3EDTA MQC-21	NEVIRAPINE 1.23 29362	MRM of 4 channels,ES+ 267.16>225.95 2.129e+005
0	NEVIRAPINE D5 1.21 8066	min MRM of 4 channels,ES+ 272.19≻226,99 5.805e+004
0.20 0.40 0.60	0.80 1.00 1.20 1.40 1.60	1.80 2.00 2.20 2.40 min

Figure 7: Representative Chromatogram of MQC Sample for Nevirapine




Figure 8: Representative Chromatogram of HQC Sample for Nevirapine

QCID	LQC Fres hCS	HQC Fres hCS	LQ CF T4 (- 70ºC±1 5ºC)	H Q CF T4 (- 70ºC±15º C)	L Q C FT 4 (- 30ºC±10º C)	H Q C F T 4 (- 30ºC±10 ≌C)
ActualConcentration(ng/mL)	67.3 950	2982.0 820	67. 40 90	2995.973 0	67.4090	2995.973 0
	74.4 968	2912.8 813	60. 72 98	2939.540 3	65.6778	2747.083 2
	74.7 140	2843.3 703	66. 34 21	2784.553 9	65.3056	2838.491 8
	67.0 256	2831.6 301	63. 61 79	2769.606 3	61.9536	2832.311 8
CalculatedConcentrati ons(ng/mL)	69.2 433	2832.1 492	68. 16 63	2804.133 6	68.3991	2860.148 3
	74.1 948	2768.7 311	68. 86 65	2766.137 1	71.2025	2844.134 0
	69.2 385	2846.5 700	60. 58 83	2788.959 2	65.0878	2824.032 6

Mean	71.4 8550	2839.2 2200	64.7184 8	2808.821 73	66.2710 7	2824.366 95
SD	3.37 0419	45.985 916	3.63067 2	65.50205 9	3.16772 1	39.76572 2
%CV	4.71	1.62	5.6 1	2. 33	4. 7 8	1. 4 1
%Nominal	106. 07	95.2 1	96. 01	93 .7 5	9 8. 3 1	9 4. 2 7
%NominalagainstCS:			90. 53	98 .9 3	9 2. 7 1	9 9. 4 8

Table 1: Freeze-Thaw Stability for Lamivudine (at -70° C \pm 15° C and -30° C \pm 10° C)

QCID	LQC Fresh CS	HQC Fresh CS	LQCF T4 (- 70ºC±15ºC)	HQ CFT 4 (- 70ºC±15ºC)	LQC FT4 (- 30ºC±10ºC)	HQ CFT 4 (- 30ºC±10ºC)
ActualConc				-		
entration(101.096	4473.282	101.0280	4490.1460	101.0280	4490.1460
ng/mL)	0	0				
	101.472	4397.241	95.22	4208.6814	90.3469	4266.7602
	9	3	55			
CalculatedC	99.0885	4444.012	93.13	4358.8388	98.5105	4318.7163
oncentratio		3	82			
ns(ng/mL)	106.433	4249.669	100.7202	4307.8322	93.9452	4241.2373
	7	4				
	105.391	4396.338	99.71	4336.0935	96.5364	4261.2762
	9	7	47			
	101.263	4245.073	98.15	4306.7060	95.1733	4238.9506
	9	6	37			
	101.323	4324.006	94.02	4295.0521	101.3453	4172.5600
	6	3	06			
Mean	102.4957	4342.723	96.82882	4302.2006	95.97627	4249.9167
	5	60		7		7

SD	2.80863	83.24794	3.140187	51.391769	3.795322	47.593640
	3	7				
%CV	2.74	1.92	3.24	1.1	3.95	1.1
				9		2
%Nominal	101.38	97.08	95.84	95.81	95.0	94.65
					0	
	%NominalagainstCS:			99.07	93.6	97.86
					4	

Table 2: Free-Thaw Stability for Nevirapine (at -70° C \pm 15° C and -30° C \pm 10° C)

StabilityHours	0 Ho	our	1	5.15hours
QCID	LQC (FreshCS)	HQC (FreshCS)	LQC (Stability)	HQC (Stability)
Actual Concentration(ng/mL)	67.3950	2982.0820	67.4090	2995.9730
	74.4968	2912.8813	72.3088	2838.8830
	74.7140	2843.3703	63.1334	2828.7747
CalculatedConcentrations(n	67.0256	2831.6301	64.8801	2850.0801
g/mL)	69.2433	2832.1492	64.2735	2812.7889
	74.1948	2768.7311	70.9170	2865.8526
	69.2385	2846.5700	65.1597	2908.7986
Mean	71.48550	2839.22200	66.77875	2850.86298
SD	3.370419	45.985916	3.833996	33.653782
%CV	4.71	1.62	5.74	1.18
%Nominal	106.07	95.21	99.07	95.16
%Nomin	%NominalagainstCS:			

Table 3: Bench - Top Stability for Lamivudine

StabilityHours		0 Hour	15.15hours		
QCID	LQC (FreshCS)	HQC (FreshCS)	LQC (Stability)	HQC (Stability)	
Actual Concentration(ng/mL)	101.0960	4473.2820	101.0280	4490.1460	
	101.4729	4397.2413	97.3552	4270.7541	
	99.0885	4444.0123	101.5451	4211.0570	
CalculatedConc	106.4337	4249.6694	98.0574	4262.8366	
	105.3919	4396.3387	103.4854	4268.2833	

Nat. Volatiles & Essent. Oils, 2021; 8(4): 15885-15901

entrations(ng/	101.2639	4245.0736	96.8297	4220.1621
mL)	101.3236	4324.0063	94.2703	4191.1023
Mean	102.49575	4342.72360	98.59052	4237.36590
SD	2.808633	83.247947	3.354532	34.199017
%CV	2.74	1.92	3.40	0.81
%Nominal	101.38	97.08	97.59	94.37
	%NominalagainstCS:			

S.No.		Solution1 (43	3.62 hours)	Solution3 (0 Hour)		
5.140.	AnalyteAr	ISArea AreaRatio		Analyte ISArea		AreaRati
	ea			Area		ο
1	720	659	0.1092	713	6791	0.1051
		7				
2	687	662	0.1036	704	6859	0.1026
		5				
3	728	710	0.1026	654	6724	0.0972
		1				
4	747	718	0.1039	622	6384	0.0975
		7				
5	753	733	0.1027	697	6767	0.1030
		4				
6	717	683	0.1048	697	7090	0.0983
		9				
		Mean	0.10447		Mean	0.1006
						2

Table 4: Bench - Top Stability for Nevirapine

 Table 5: Short-Term Stock Solution Stability for Lamivudine at LQC level

Short-Term Stock Solution Stability for Lamivudine = 103.83%

Solution 1: Analyte (43.62 hours) at Room Temperature + IS (0 Hour) at Refrigerator Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator

 Table 6: Short-Term Stock Solution Stability of Lamivudine 13C 15N2 at LQC level

S.No.	Solution2 (43.62 hours)			Solution3 (0 Hour)			
5.140.	AnalyteAr	ISAr	AreaRatio	AnalyteA	ISArea	AreaRati	
	ea	ea		rea		о	
1	738	695	9.4268	713	6791	9.5245	
		7					
2	751	727	9.6804	704	6859	9.7429	
		0					
3	772	737	9.5518	654	6724	10.2813	
		4					
4	739	739	10.0014	622	6384	10.2637	
		1					
5	705	693	9.8383	697	6767	9.7088	
		6					
6	731	704	9.6402	697	7090	10.1722	
		7					
		Mea	9.68982		Mean	9.94890	
		n					

Short-Term Stock Solution Stability for Lamivudine 13C 15N2 = 97.40% Solution 2: Analyte (0 Hour) at Refrigerator + IS (43.62 hours) at Room Temperature

S.N		Solution1 (43.62 hours)			Solution3 (0 Hour)		
0.	Analyt	IS	AreaRatio	Analyt	ISAre	AreaRatio	
	eArea	Ar		eArea	а		
		ea					
1	30337	6698	4.5295	27956	6262	4.4647	
2	28762	5996	4.7972	28424	6308	4.5058	
3	30565	6626	4.6128	28784	6472	4.4476	
4	31443	6846	4.5930	27240	5951	4.5774	
5	31956	6828	4.6801	26067	5954	4.3782	
6	30789	6594	4.6695	27261	6121	4.4540	
		Mean	4.64702		Mean	4.47128	

Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator

Table 7: Short-Term Stock Solution Stability for Lamivudine at HQC

Short-Term Stock Solution Stability for Lamivudine = 103.93%Solution 1: Analyte (43.62 hours) atRoom Temperature + IS (0 Hour) at Refrigerator Solution 3: Analyte (0Hour) atRefrigerator + IS (0 Hour) at RefrigeratorHour) at

S.No. Solution2 (43.62 hours)	Solution3 (0 Hour)
-------------------------------	--------------------

	Analyte	ISAre	AreaRatio	Analy	ISA	AreaRatio
	Area	а		teAre	rea	
				а		
1	30752	6406	0.2083	27956	626	0.2240
					2	
2	31108	6773	0.2177	28424	630	0.2219
					8	
3	31530	6981	0.2214	28784	647	0.2248
					2	
4	32740	7303	0.2231	27240	595	0.2185
					1	
5	31073	6740	0.2169	26067	595	0.2284
					4	
6	29361	6482	0.2208	27261	612	0.2245
					1	
		Mea	0.21803		Mean	0.22370
		n				

Table 8: Short-Term Stock Solution Stability of Lamivudine 13C 15N2 at HQC

Short-Term Stock Solution Stability for Lamivudine 13C 15N2 = 97.47%

Solution 2: Analyte (0 Hour) at Refrigerator + IS (43.62 hours) at Room Temperature Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator

S.No.		Solution	1 (43.62 hours)	Solution3 (0 Hour)			
5.100.	Analyte	ISArea	AreaRatio	AnalyteAre	ISArea	AreaRatio	
	Area			а			
1	1289	6713	0.1921	1456	753	0.1933	
					1		
2	1365	6969	0.1958	1331	707	0.1881	
					5		
3	1529	7775	0.1966	1299	642	0.2024	
					1		
4	1499	7830	0.1915	1294	662	0.1953	
					6		
5	1517	7800	0.1945	1454	735	0.1976	
					8		
6	1411	7228	0.1952	1429	752	0.1900	
					0		
		Mean	0.19428		Mean	0.19445	

Table 9: Short-Term Stock Solution Stability for Nevirapine at LQC level Short-Term Stock Solution Stability for Nevirapine D5 = 99.91% Solution 1: Analyte (43.62 hours) at Room Temperature + IS (0 Hour) at Refrigerator Solution 3: Analyte (0 Hour) at

Refrigerator + IS (0 Hour) at Refrigerator

S.No.		Solution	2 (43.62 hours)	Solution3 (0 Hour)			
5.140.	Analy	ISA	AreaRatio	AnalyteAre	ISArea	AreaRat	
	teAre	rea		а		io	
	а						
1	1544	768	4.9741	1456	7531	5.1724	
		0					
2	1640	839	5.1207	1331	7075	5.3156	
		8					
3	1709	823	4.8180	1299	6421	4.9430	
		4					
4	1510	765	5.0709	1294	6626	5.1206	
		7					
5	1403	708	5.0499	1454	7358	5.0605	
		5					
6	1526	773	5.0662	1429	7520	5.2624	
		1					
		Mean	5.01663		Mean	5.14575	

Table 10: Short-Term Stock Solution Stability of Nevirapine D5 at LQC level

Short-Term Stock Solution Stability for Nevirapine D5 = 97.49%

Solution 2: Analyte (0 Hour) at Refrigerator + IS (43.62 hours) at Room Temperature Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator

S.No.		Solution	1 (43.62 hours)	Solution3 (0 Hour)			
5.110.	Anal	ISA	AreaRatio	AnalyteAre	ISArea	AreaRati	
	yteA	rea		а		0	
	rea						
1	5872	660	8.8958	60014	7010	8.5611	
-	3	1					
2	5647	642	8.7875	57281	6636	8.6324	
2	9	7					
3	6284	731	8.5925	54311	6301	8.6195	
J	2	4					
4	6487	733	8.8403	50589	5825	8.6847	
7	1	8					
5	6454	738	8.7431	49522	5795	8.5458	
5	2	2					
6	6195	704	8.7950	55490	6377	8.7015	

7	5			
	Mean	8.77570	Mean	8.62417

S.N		Solution	2 (43.62 hours)	Solution3 (0 Hour)			
0.	Analyte	ISA	AreaRatio	Analyte	ISArea	AreaRa	
0.	Area	rea		Area		tio	
1	62121	718	0.1157	60014	7010	0.1168	
		9					
2	70968	809	0.1140	57281	6636	0.1158	
		1					
3	69450	781	0.1126	54311	6301	0.1160	
		9					
4	65413	742	0.1135	50589	5825	0.1151	
		5					
5	60717	681	0.1122	49522	5795	0.1170	
		3					
6	59965	687	0.1146	55490	6377	0.1149	
		4					
		Mean	0.11378		Mean	0.1159	
						6	

Table 11: Short-Term Stock Solution Stability of Nevirapine at HQC Short-Term Stock Solution Stability for Nevirapine = 10 Solution 1: Analyte (43.62 hours) at Room Temperature + IS (0 Hour) at Refrigerator Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator Table 12: Short-Term Stock Solution Stability of Nevirapine D5 at HQC Short-Term Stock Solution Stability for Nevirapine D5 = 98.12% Solution 2: Analyte (0 Hour) at Refrigerator + IS (43.62 hours) at Room Temperature Solution 3: Analyte (0 Hour) at Refrigerator + IS (0 Hour) at Refrigerator

CONCLUSION

A validated stability-indicating LC/MS/MS assay method was established to study the degradation pattern of Lamivudine and Nevirapine under hydrolysis, oxidation, photolysis and thermal stress conditions.

References

Joseph E. Rower, Brandon Klein, Lane R. Bushman, And Peter L. <u>Anderson</u>. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma.Biomed Chromatogr. 2012 Jan; 26(1): 12–20

AlperDaskapan, Kai van Hateren, YmkjeStienstra, Jos Kosterink, Tjip van der Werf, DaanTouw, Jan-Willem Alffenaar. Development and Validation of a Bioanalytical Method for the Simultaneous Determination of 14 Antiretroviral Drugs using Liquid Chromatography-Tandem Mass Spectrometry. Journal of Applied Bioanalysis. Vol. 4. No. 2. pages 37-50 (2018)

D Chang 1, S J Kolis, K H Linderholm, T F Julian, R Nachi, A M Dzerk, P P Lin, J W Lee, S K Bansal. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2005 Jul 1;38(3):487-96.

Madhavi, S., and A. P. Rani. Bioanalytical Method Development And Validation For The Determination Of Sofosbuvir From Human Plasma⁻ International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 3, Mar. 2017, pp. 35-41,

E. De Clercq. Antivirals and antiviral stategies.Nat. Rev. Microbiol. 2: 704–720 (2004).

Manish Yadav, Ajay Gupta, PuranSinghal, and Pranav S. Shrivastav.Development and Validation of a Selective and Rapid LC–MS–MS Method for the Quantification of Abacavir in Human Plasma.Journal of Chromatographic Science, Vol. 48, September 2010

Srinivasa Reddy, Licto Thomas, K. S. Santoshkumar, NirmalaNayak, ArindamMukhopadhyay and SaralThangam A LC–MS/MS method with column coupling technique for simultaneous estimation of lamivudine, zidovudine and nevirapine in human plasma. Journal of Analytical Science and Technology (2016) 7:17

Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, Shrivastav P. Highthroughput LC–MS/MS method for simultaneous quantification oflamivudine, stavudine and nevirapine in human plasma. J Chromatogr B AnalytTechnol Biomed Life Sci. 2007;853:320–32

Zhou L, Cungang D, Qinghua G, Zhen Z, Xiaojin Z, Xiaofen L. Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC–MS/MS and its application to pharmacokinetic study in clinic.BiomedChroma. 2010;24:926–34.

<u>Prashant S. Devrukhakar</u>, <u>M. Shiva Shankar</u>, <u>G. Shankar</u>, <u>R. Srinivas</u>. A stability-indicating LC–MS/MS method for zidovudine: Identification, characterization and toxicity prediction of two major acid degradation products. <u>J Pharm Anal.</u> 2017 Aug; 7(4): 231–236.

Maria Inês R. M. SantoroAndréia M. TaborianskiAnil Kumar SinghErika R. M. Kedor-Hackmann. Stability-indicating methods for quantitative determination of zidovudine and stavudine in capsules.Quím. Nova 29 (2) • Apr 2

BlessyMRuchi D.PatelPrajesh N.PrajapatiY.K.Agrawal. Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis Volume 4, Issue 3, June 2014, Pages 159-165

M. Nebsen, Eman S. Elzanfaly. Stability-Indicating Method and LC–MS-MS Characterization of Forced Degradation Products of Sofosbuvir. Journal of Chromatographic Science, Volume 54, Issue 9, 17 October 2016, Pages 1631–1640

NarenderanS.T, RameshJBabuB, MeyyanathanS.N. A stability-indicating LC–MS/MS method optimization for Pemetrexed through design of experiments: Identification and characterization of major oxidative degradation product. Journal of Pharmaceutical and Biomedical Analysis Volume 183, 10 May 2020, 113150

Ankit Kanaiyalal Rochani,1 Margaret Wheatley,2 Brian Edward Oeffinger,2 John Robert Eisenbrey,3 and Gagan Kaushal. LC-MS based stability-indicating method for studying the degradation of lonidamine under physical and chemical stress conditions. Res Pharm Sci. 2020 Aug; 15(4): 312–322